Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a GSK-3β inhibitor with an IC₅₀ of 2.0 µM. IC50 & Target: Calcium Channel^[1]. In Vitro: Cromolyn sodium (Disodium Cromoglycate; FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. In Vivo: Pretreatment of IIR mice with Cromolyn sodium (Disodium Cromoglycate; FPL-670) prior to ischemia exhibited no changes of ET-1 levels, injury score and inflammation (P>0.05, PreCr vs. M groups). In conclusion, administration of Cromolyn (sodium) after reperfusion, but not prior to ischemia, attenuates IIRI by downregulating ET-1 and suppressing sustained MC activation^[1]. Cromolyn (sodium) has a role in the prevention of Chronic lung disease(CLD). Cromolyn (sodium) cannot be recommended for the prevention of CLD in preterm infants^[2].